181 related articles for article (PubMed ID: 38333210)
1. Epacadostat stabilizes the apo-form of IDO1 and signals a pro-tumorigenic pathway in human ovarian cancer cells.
Rossini S; Ambrosino S; Volpi C; Belladonna ML; Pallotta MT; Panfili E; Suvieri C; Macchiarulo A; Mondanelli G; Orabona C
Front Immunol; 2024; 15():1346686. PubMed ID: 38333210
[TBL] [Abstract][Full Text] [Related]
2. The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1.
Panfili E; Mondanelli G; Orabona C; Gargaro M; Volpi C; Belladonna ML; Rossini S; Suvieri C; Pallotta MT
Front Immunol; 2023; 14():1134551. PubMed ID: 37122718
[TBL] [Abstract][Full Text] [Related]
3. Identification of a 2-propanol analogue modulating the non-enzymatic function of indoleamine 2,3-dioxygenase 1.
Albini E; Coletti A; Greco F; Pallotta MT; Mondanelli G; Gargaro M; Belladonna ML; Volpi C; Bianchi R; Grohmann U; Macchiarulo A; Orabona C
Biochem Pharmacol; 2018 Dec; 158():286-297. PubMed ID: 30391205
[TBL] [Abstract][Full Text] [Related]
4. The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells.
Jochems C; Fantini M; Fernando RI; Kwilas AR; Donahue RN; Lepone LM; Grenga I; Kim YS; Brechbiel MW; Gulley JL; Madan RA; Heery CR; Hodge JW; Newton R; Schlom J; Tsang KY
Oncotarget; 2016 Jun; 7(25):37762-37772. PubMed ID: 27192116
[TBL] [Abstract][Full Text] [Related]
5. A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer.
Kristeleit R; Davidenko I; Shirinkin V; El-Khouly F; Bondarenko I; Goodheart MJ; Gorbunova V; Penning CA; Shi JG; Liu X; Newton RC; Zhao Y; Maleski J; Leopold L; Schilder RJ
Gynecol Oncol; 2017 Sep; 146(3):484-490. PubMed ID: 28698009
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Apo-Form Selective Inhibition of Indoleamine 2,3-Dioxygenase*.
Ortiz-Meoz RF; Wang L; Matico R; Rutkowska-Klute A; De la Rosa M; Bedard S; Midgett R; Strohmer K; Thomson D; Zhang C; Mebrahtu M; Guss J; Totoritis R; Consler T; Campobasso N; Taylor D; Lewis T; Weaver K; Muelbaier M; Seal J; Dunham R; Kazmierski W; Favre D; Bergamini G; Shewchuk L; Rendina A; Zhang G
Chembiochem; 2021 Feb; 22(3):516-522. PubMed ID: 32974990
[TBL] [Abstract][Full Text] [Related]
7. Indoleamine 2,3-dioxygenase 1 in circumventing checkpoint inhibitor responses: Updated.
Charehjoo A; Majidpoor J; Mortezaee K
Int Immunopharmacol; 2023 May; 118():110032. PubMed ID: 36933494
[TBL] [Abstract][Full Text] [Related]
8. Distinct roles of immunoreceptor tyrosine-based motifs in immunosuppressive indoleamine 2,3-dioxygenase 1.
Albini E; Rosini V; Gargaro M; Mondanelli G; Belladonna ML; Pallotta MT; Volpi C; Fallarino F; Macchiarulo A; Antognelli C; Bianchi R; Vacca C; Puccetti P; Grohmann U; Orabona C
J Cell Mol Med; 2017 Jan; 21(1):165-176. PubMed ID: 27696702
[TBL] [Abstract][Full Text] [Related]
9. Target exposure and pharmacodynamics study of the indoleamine 2,3-dioxygenase-1 (IDO-1) inhibitor epacadostat in the CT26 mouse tumor model.
Poncelet L; Ait-Belkacem R; Marillier R; Gomes B; Stauber J
J Pharm Biomed Anal; 2019 Jun; 170():220-227. PubMed ID: 30933897
[TBL] [Abstract][Full Text] [Related]
10. Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.
Labadie BW; Bao R; Luke JJ
Clin Cancer Res; 2019 Mar; 25(5):1462-1471. PubMed ID: 30377198
[TBL] [Abstract][Full Text] [Related]
11. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy.
Fujiwara Y; Kato S; Nesline MK; Conroy JM; DePietro P; Pabla S; Kurzrock R
Cancer Treat Rev; 2022 Nov; 110():102461. PubMed ID: 36058143
[TBL] [Abstract][Full Text] [Related]
12. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
Kim M; Tomek P
Front Immunol; 2021; 12():636081. PubMed ID: 33708223
[TBL] [Abstract][Full Text] [Related]
13. Indoleamine 2,3-dioxygenase 1 (IDO1): an up-to-date overview of an eclectic immunoregulatory enzyme.
Pallotta MT; Rossini S; Suvieri C; Coletti A; Orabona C; Macchiarulo A; Volpi C; Grohmann U
FEBS J; 2022 Oct; 289(20):6099-6118. PubMed ID: 34145969
[TBL] [Abstract][Full Text] [Related]
14. What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past.
Yao Y; Liang H; Fang X; Zhang S; Xing Z; Shi L; Kuang C; Seliger B; Yang Q
J Exp Clin Cancer Res; 2021 Feb; 40(1):60. PubMed ID: 33557876
[TBL] [Abstract][Full Text] [Related]
15. Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy.
Zhang Y; Hu Z; Zhang J; Ren C; Wang Y
Eur J Med Chem; 2022 Aug; 238():114524. PubMed ID: 35696861
[TBL] [Abstract][Full Text] [Related]
16. IDO1 Is a Therapeutic Target for Pancreatic Cancer-Associated Depression.
Hue JJ; Graor HJ; Zarei M; Katayama ES; Ji K; Hajihassani O; Loftus AW; Vaziri-Gohar A; Winter JM
Mol Cancer Ther; 2022 Dec; 21(12):1810-1822. PubMed ID: 36190971
[TBL] [Abstract][Full Text] [Related]
17. Targeting Tryptophan Catabolism in Ovarian Cancer to Attenuate Macrophage Infiltration and PD-L1 Expression.
Crump LS; Floyd JL; Kuo LW; Post MD; Bickerdike M; O'Neill K; Sompel K; Jordan KR; Corr BR; Marjon N; Woodruff ER; Richer JK; Bitler BG
Cancer Res Commun; 2024 Mar; 4(3):822-833. PubMed ID: 38451784
[TBL] [Abstract][Full Text] [Related]
18. First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.
Beatty GL; O'Dwyer PJ; Clark J; Shi JG; Bowman KJ; Scherle PA; Newton RC; Schaub R; Maleski J; Leopold L; Gajewski TF
Clin Cancer Res; 2017 Jul; 23(13):3269-3276. PubMed ID: 28053021
[No Abstract] [Full Text] [Related]
19. Advances in the discovery and development of selective heme-displacing IDO1 inhibitors.
Sun L
Expert Opin Drug Discov; 2020 Oct; 15(10):1223-1232. PubMed ID: 32568559
[TBL] [Abstract][Full Text] [Related]
20. Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer.
Chen B; Alvarado DM; Iticovici M; Kau NS; Park H; Parikh PJ; Thotala D; Ciorba MA
Cancer Immunol Res; 2020 Apr; 8(4):451-464. PubMed ID: 32127391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
